Cyclophosphamide/thiotepa/mitoxantrone with autologous stem cell rescue for high risk stage II and stage III breast cancer

被引：0
|
作者：
Krüger, WH [1 ]
Kröger, N [1 ]
Königmann, M [1 ]
Berdel, WE [1 ]
Fuss, H [1 ]
Schultze, W [1 ]
Gieseking, F [1 ]
Schäfer-Eckart, K [1 ]
Möbus, V [1 ]
Frickhofen, N [1 ]
Wandt, H [1 ]
Illiger, HJ [1 ]
Metzner, B [1 ]
Kolbe, K [1 ]
Wörmann, B [1 ]
Trümper, L [1 ]
Huber, C [1 ]
Maass, H [1 ]
Jonat, W [1 ]
Zander, AR [1 ]
机构：
[1] Univ Hamburg, Hosp Eppendorf, Dept Hematol Oncol, BMT, D-20246 Hamburg, Germany
来源：
BONE MARROW TRANSPLANTATION | 1998年 / 22卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
SP31
引用
收藏
页码：S18 / S20
页数：3
相关论文
共 50 条
  • [21] Anemia in stage II and III breast cancer patients treated with doxorubicin and cyclophosphamide (AC).
    Kirshner, J
    Hatch, M
    Hennessy, DD
    Tannous, RE
    Fridman, M
    Gupta, S
    BLOOD, 2002, 100 (11) : 498B - 499B
  • [22] Long-term follow-up of autologous hematopoietic stem cell transplantation for stage II/III breast cancer.
    Meyer, Andrew D.
    Tolentino, Angelica L.
    Bitran, Jacob D.
    Klein, Leonard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
    David Aguiar Bujanda
    Uriel Bohn Sarmiento
    Miguel Ángel Cabrera Suárez
    Marta Pavcovich Ruiz
    Miguel Ángel Limeres González
    José Aguiar Morales
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 332 - 338
  • [24] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
    Bujanda, DA
    Sarmiento, UB
    Suárez, MAC
    Ruiz, MP
    González, MAL
    Morales, JA
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (05) : 332 - 338
  • [25] High-dose chemotherapy with autologous stem cell rescue in breast cancer
    Dillman, RO
    Barth, NM
    Nayak, SK
    DeLeon, C
    OConnor, A
    Morrelli, L
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (03) : 277 - 289
  • [26] High-dose busulfan, melphalan and thiotepa (BUMELTT) followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.
    Holmberg, LA
    Demirer, T
    Sciffman, K
    Rowley, SD
    Buckner, CD
    Goodman, G
    Maziarz, R
    Appelbaum, F
    Bensinger, WI
    BLOOD, 1997, 90 (10) : 1705 - 1705
  • [27] Tandem High-Dose Chemotherapy with Autologous Stem Cell Rescue using Thiotepa/Cyclophosphamide and Busulfan/Melphalan Regimens in Two Cases of High-Risk Neuroblastoma
    Mizushima, Yoshitaka
    Mitani, Yuichi
    Oshima, Koichi
    Mori, Makiko
    Fukuoka, Kohei
    Arakawa, Yuki
    Kawashima, Hiroshi
    Nakazawa, Atsuko
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [28] Thiotepa-based High-dose Chemotherapy with Autologous Stem Cell Rescue in Children with High-risk Medulloblastoma
    Sajiki, Daichi
    Maemura, Ryo
    Yamamori, Ayako
    Wakamatsu, Manabu
    Sakaguchi, Hirotoshi
    Yoshida, Nao
    Hatano, Hisashi
    Kato, Koji
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S55 - S55
  • [29] High-dose therapy with autologous stem cell rescue in patients with breast cancer at high risk relapse.
    Farjami, S
    Kancherla, R
    Qureshi, Z
    Hoang, A
    Puccio, C
    Mittelman, A
    Seiter, K
    Ahmed, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 83S - 83S
  • [30] Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children
    Fries, Carol
    Girvin, Angela R.
    Korones, David N.
    Weintraub, Lauren
    Fitzpatrick, Lorna
    Andolina, Jeffrey R.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (08) : E1223 - E1227
12345